FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer

The FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.

Cancer Currents: An NCI Cancer Research Blog